Ser571
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser571  -  SCN5A (human)

Site Information
PWPLRRtsAQGQPsP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27281507

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 2 ) , mass spectrometry (in vitro) ( 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:
'heart, artery' ( 1 ) , 293 (epithelial) ( 3 ) , heart ( 2 ) , myocyte-heart ( 1 )

Upstream Regulation
Putative in vivo kinases:
CAMK2A (human) ( 1 , 2 )
Kinases, in vitro:
CAMK2A (human) ( 3 )
Treatments:
KN-93 ( 2 )

Downstream Regulation
Effects of modification on SCN5A:
activity, induced ( 1 , 2 ) , enzymatic activity, induced ( 1 ) , intracellular localization ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
atrial fibrillation ( 1 ) , cardiomyopathy ( 2 )

References 

1

Greer-Short A, et al. (2019) Calmodulin kinase II regulates atrial myocyte late sodium current, calcium handling, and atrial arrhythmia. Heart Rhythm
31622781   Curated Info

2

Yoo S, et al. (2018) Oxidative stress creates a unique, CaMKII-mediated substrate for atrial fibrillation in heart failure. JCI Insight 3
30385719   Curated Info

3

Herren AW, et al. (2015) CaMKII Phosphorylation of Na(V)1.5: Novel in Vitro Sites Identified by Mass Spectrometry and Reduced S516 Phosphorylation in Human Heart Failure. J Proteome Res 14, 2298-311
25815641   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.